Overcoming Immunological Barriers for Preclinical Studies of Cardiac Stem Cell
Abstract
Many veterans suffer from ischemic cardiomyopathy partly resulting from exposure to Agent Orange. Due to the limited supply of donor hearts and potential complications from chronic immunosuppressive therapy, investigators have turned to therapeutic approaches aimed at improving myocardial function, namely, cell transplantation. The purpose of this proposal is to generate non-immunogenic human embryonic stem cell-derived left ventricular cardiomyocytes as a potential off-the- shelf candidate for cardiac cell transplantation. Success of this proposal would address the increasing health burden of veterans suffering from ischemic cardiomyopathy. A nonimmunogenic universal donor cell line (Elf1) was previously developed to bypass host immune recognition and response. We have made progress in expanding and characterizing the pluripotency of this cell line. We confirmed that these cells express high levels of pluripotency markers indicative of their stem cell state. We are currently transitioning them from a feeder to feeder-free system as well as switching from Naive to Primed state that is required for our cardiac differentiation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2020
- Accession Number
- AD1110770
Entities
People
- Arash Pezhouman
Organizations
- University of California, Los Angeles